Ocugen (OCGN) Competitors $0.97 -0.01 (-1.39%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. CRMD, NAGE, WVE, AUPH, ELVN, ABCL, PAHC, VERV, COLL, and AKBAShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include CorMedix (CRMD), Niagen Bioscience (NAGE), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Ocugen vs. Its Competitors CorMedix Niagen Bioscience WAVE Life Sciences Aurinia Pharmaceuticals Enliven Therapeutics AbCellera Biologics Phibro Animal Health Verve Therapeutics Collegium Pharmaceutical Akebia Therapeutics CorMedix (NASDAQ:CRMD) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership. Do institutionals & insiders have more ownership in CRMD or OCGN? 34.2% of CorMedix shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 5.3% of CorMedix shares are owned by company insiders. Comparatively, 4.3% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, CRMD or OCGN? CorMedix has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, suggesting that its stock price is 320% more volatile than the S&P 500. Is CRMD or OCGN more profitable? CorMedix has a net margin of 20.81% compared to Ocugen's net margin of -1,271.12%. CorMedix's return on equity of 22.57% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets CorMedix20.81% 22.57% 17.02% Ocugen -1,271.12%-223.00%-92.20% Do analysts rate CRMD or OCGN? CorMedix presently has a consensus target price of $17.14, indicating a potential upside of 39.15%. Ocugen has a consensus target price of $6.00, indicating a potential upside of 518.30%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor CRMD or OCGN? In the previous week, CorMedix had 23 more articles in the media than Ocugen. MarketBeat recorded 29 mentions for CorMedix and 6 mentions for Ocugen. CorMedix's average media sentiment score of 0.51 beat Ocugen's score of 0.44 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 6 Very Positive mention(s) 5 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, CRMD or OCGN? CorMedix has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M19.22-$17.93M$0.2256.00Ocugen$4.05M69.97-$54.05M-$0.19-5.11 SummaryCorMedix beats Ocugen on 13 of the 16 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$287.39M$2.84B$5.45B$8.90BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-5.1121.1526.3919.66Price / Sales69.97259.49406.95110.26Price / CashN/A41.2925.8827.49Price / Book9.707.247.925.42Net Income-$54.05M-$55.05M$3.15B$248.34M7 Day Performance-6.24%-1.01%0.66%0.82%1 Month Performance14.94%5.98%4.95%5.01%1 Year Performance-40.28%0.83%32.31%18.10% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.3732 of 5 stars$0.97-1.4%$6.00+518.3%-37.4%$287.39M$4.05M-5.1180High Trading VolumeCRMDCorMedix1.5379 of 5 stars$16.56+21.7%$15.83-4.4%+184.5%$1.12B$43.47M75.2830Analyst ForecastHigh Trading VolumeNAGENiagen Bioscience1.4827 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.07B$99.60M80.24120WVEWAVE Life Sciences4.3088 of 5 stars$6.94+5.6%$20.50+195.5%+30.3%$1.07B$108.30M-8.26240AUPHAurinia Pharmaceuticals2.5141 of 5 stars$7.83+0.8%$11.50+46.9%+48.3%$1.06B$235.13M27.96300News CoveragePositive NewsELVNEnliven Therapeutics2.2379 of 5 stars$20.27-4.8%$39.60+95.4%-14.2%$994.68MN/A-10.5650ABCLAbCellera Biologics2.7701 of 5 stars$3.33-2.3%$8.33+150.3%+15.9%$993.75M$23.11M-5.95500PAHCPhibro Animal Health3.6323 of 5 stars$24.46+2.4%$20.80-15.0%+52.3%$991.36M$1.02B31.361,940VERVVerve Therapeutics3.6125 of 5 stars$11.11+0.4%$14.75+32.8%+130.1%$989.90M$32.33M-5.26110COLLCollegium Pharmaceutical3.9692 of 5 stars$29.88+0.2%$43.75+46.4%-8.2%$960.10M$664.28M24.49210AKBAAkebia Therapeutics4.2249 of 5 stars$3.64-1.1%$6.75+85.4%+256.9%$956.01M$160.18M-17.33430Positive News Related Companies and Tools Related Companies CorMedix Alternatives Niagen Bioscience Alternatives WAVE Life Sciences Alternatives Aurinia Pharmaceuticals Alternatives Enliven Therapeutics Alternatives AbCellera Biologics Alternatives Phibro Animal Health Alternatives Verve Therapeutics Alternatives Collegium Pharmaceutical Alternatives Akebia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
